CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients

    Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.

    May 17, 2016| Arthur N. Brodsky, PhD
  • FDA Regulatory Definitions

    You heard that a drug in clinical trials was Fast Tracked. Or you heard that a treatment…

    February 12, 2016| Alexandra Mulvey
  • FDA Approval Expands Immunotherapy Options for Advanced Melanoma

    Immunotherapy combinations continue to shine against melanoma.

    January 27, 2016| Arthur N. Brodsky, PhD
  • Immunotherapy Approvals in 2015

    In 2015, the FDA approved more immunotherapies than in any prior year.

    December 24, 2015| Alexandra Mulvey
  • Second Antibody FDA-Approved Against Multiple Myeloma

    Elotuzumab (Empliciti) is the second antibody for myeloma approved in just two weeks.

    December 1, 2015| Arthur N. Brodsky, PhD
  • Nivolumab Becomes First FDA-Approved Checkpoint Blockade for Kidney Cancer

    New hope now exists for patients with advanced kidney cancer.

    November 24, 2015| Arthur N. Brodsky, PhD
  • First Monoclonal Antibody for Multiple Myeloma Receives FDA Approval

    Daratumumab (Darzalex®) is the first approved immunotherapy that targets CD38—a protein found in most multiple myeloma cells.

    November 20, 2015| Alexandra Mulvey
  • FDA Approves Immunotherapy to Help Prevent Relapse of Melanoma

    The immunotherapy drug ipilimumab (Yervoy®) can now be used to help prevent relapse after surgery.

    October 30, 2015| Matthew Tontonoz
  • FDA Approves First in a New Class of Immunotherapies

    Amgen’s oncolytic virus immunotherapy, T-VEC, gets the green light from the FDA.

    October 27, 2015| Matthew Tontonoz
Previous Page
1 2 3 4 5
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute